Group 1 - AstraZeneca plans to establish a cell therapy manufacturing and supply base along with an innovation center in Shanghai, aiming to be the first global drugmaker with comprehensive cell therapy capabilities in China [1][2] - The new facility will focus on the production and supply of autologous CART cell therapies for China and other Asian markets [2]